Navidea Biopharmaceuticals, Inc. Navidea Biopharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Careers
  • Technology
    • Overview
    • Grant Funding
  • Pipeline
  • News & Media
    • Press Releases
    • Events
    • Publications
    • In the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Press Releases

News & Media

News & Media

  • Press Releases
  • Events
  • Publications
  • In the News

Navidea Awarded $1.67M Fast Track NIH SBIR Grant for Evaluation of Lymphoseek® in Cervical Cancer

Sep 23, 2014

Navidea Receives Orphan Drug Designation from FDA for Use of Lymphoseek® in Head and Neck Cancers

Sep 18, 2014

Navidea Enters Lymphoseek® Development and Commercialization Agreement for China

Sep 4, 2014

Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million

Aug 6, 2014

Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014

Jul 29, 2014

Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results

Jul 17, 2014

Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases

Jul 16, 2014

Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014

Jul 2, 2014

Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference

Jun 17, 2014

U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy

Jun 13, 2014
    • 1...
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    • ...45
    © 2025 Navidea Biopharmaceuticals, Inc. All Rights Reserved.
    linkedin
    Privacy Policy Disclaimer Sitemap